Author Archives: Lu Rahman

#AI / data analytics / healthtech / informatics #Covid-19 #Drug development

Is virtual reality the new tool for COVID-19 drug design?

Bristol scientists have demonstrated a new virtual reality [VR] technique which should help in developing drugs against the SARS-CoV-2 virus – and enable researchers to share models and collaborate in new ways. The innovative tool, created by University of Bristol researchers, and published in the Journal of Chemical Information and… Read More

#Covid-19 #Editor's Choice #News

#Clinical trials #Covid-19 #Immunology / Virology & Vaccines

Medicago and GSK start of Phase II/III clinical trials of adjuvanted COVID-19 vaccine candidate

Medicago, a biopharmaceutical company headquartered in Quebec City, and GSK are starting Phase II/III clinical trials of its plant-derived vaccine candidate for COVID-19 to evaluate its efficacy, safety, and immunogenicity. Based on the positive Phase I results, Medicago has decided to launch the Phase II/III clinical trial with GSK’s pandemic… Read More

#Covid-19 #News

#Covid-19 #Immunology / Virology & Vaccines

CureVac’s COVID-19 vaccine candidate, suitable for standard fridge temperature logistics 

CureVac says its mRNA-based COVID-19 vaccine candidate, CVnCoV, remains stable and within defined specifications for at least three months when stored at a standard refrigerator temperature of +5°C (+41°F) and up to 24 hours as ready-to-use vaccine when stored at room temperature. “Transport and storage of vaccines requiring ultra-low temperature… Read More

#Covid-19 #News

#Clinical specialities #Covid-19 #Pneumonia

Campaign and conference shine light on importance of pneumonia research

The PneumoLight campaign, in collaboration with Pfizer – and coinciding with World Pneumonia Day – will see 232 buildings and monuments from 48 different countries will be illuminated in blue. The project involves Dr. Catia Cilloniz, a researcher at the Hospital Clínic of Barcelona, the University of Barcelona (UB), the Barcelona… Read More

#Covid-19 #News

#Biopharmaceuticals #Oncology #Therapeutics

Merck’s acquisition of VelosBio will boost oncology push

Merck (known as MSD outside the United States and Canada), is paying  $2.75 billion for VelosBio, a clinical-stage biopharmaceutical company committed to developing first-in-class cancer therapies targeting receptor tyrosine kinase-like orphan receptor 1 (ROR1). VelosBio’s lead investigational candidate is VLS-101, an antibody-drug conjugate (ADC) targeting ROR1 that is currently being… Read More

#Cancer Research #News

#Covid-19 #Immunology / Virology & Vaccines

Life sciences report highlights implications of early COVID-19 vaccines data

FinnCap’s latest Rude Health Life Sciences Sector Report focuses on the implications of early COVID-19 vaccine data. This comes as Pfizer and BioNTech have announced their COVID-19 vaccine candidate has so far been found to be 90% effective in preventing COVID-19. Mark Brewer, Director of Research for finnCap, commented: "While the… Read More

#Business & Investment #Covid-19 #Editor's Choice #News

#Biotechnology #Drug development #Drug discovery #Ingredients / APIs / Fine chemicals #Pharmacokinetics / Pharmacodynamics

Evotec expands UK site into drug discovery & development centre

Evotec is expanding its campus in Abingdon, Oxfordshire, UK, into a major, fully-integrated, co-located discovery and development centre to be named Dorothy Crowfoot Hodgkin Campus. Adding a new building, which will house up to 100 biologists by the end of the year, will bring together all the key functions for… Read More

#News

#Covid-19 #Immunology / Virology & Vaccines

Croda contract for Pfizer COVID-19 vaccine

Croda, the speciality chemical company has entered into an agreement with Pfizer to supply novel excipients used in the manufacture of a COVID-19 vaccine candidate. The contract runs for five years and awards Croda an initial supply contract for four component excipients used in the production of the vaccine candidate… Read More

#Covid-19 #News

#Covid-19 #Immunology / Virology & Vaccines #Pharmaceutical

It’s never been more important to talk about vaccines, says head of pharma organisation

Richard Torbett, Chief Executive, ABPI says vaccines are one of our best hopes for eradicating COVID-19 and why the ABPI is launching a campaign to highlight this. “COVID-19 has put shone a spotlight on the pharmaceutical industry like never before. Millions of people all over the world are living under… Read More

#Covid-19 #Editor's Choice #News #Opinion

#Covid-19 #Immunology / Virology & Vaccines

Russia says Sputnik V vaccine against COVID-19 phase III clinical trials shows 92% efficacy

The National Research Center for Epidemiology and Microbiology (Gamaleya Center) and the Russian Direct Investment Fund (RDIF) have announced that the Sputnik V vaccine demonstrated high efficacy of 92%. The human adenoviral vectors vaccine against coronavirus was registered on the 11 August under the emergency use authorisation mechanism. The confirmation… Read More

#Covid-19 #Editor's Choice #News #Trending News

#Gene therapy #Pharmaceutical

CEVEC signs agreement with Roche for gene therapy technology

CEVEC Pharmaceuticals has signed an option and license agreement with Roche for the use of its newly launched ELEVECTA Technology for large scale manufacturing of adeno‐associated virus (AAV) vectors for gene therapy applications. Under the terms of the agreement, CEVEC will grant Roche, and Spark Therapeutics, a member of the… Read More

#News

#Drug discovery

Collaboration aims to accelerate drug discovery in mental health care

COMPASS Pathways joins the Psychiatry Consortium in a collaboration to accelerate drug discovery in mental health care COMPASS Pathways (CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, has joined the Psychiatry Consortium, an international collaboration to accelerate drug discovery and development… Read More

#News